Structure of 17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecanoic Acid CAS 1143516-05-5

17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecanoic Acid CAS 1143516-05-5

Identification

CAS Number

1143516-05-5

Name

17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecanoic Acid

Synonyms

1143516-05-5 [RN]
17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecan-1-oic acid
17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecan-1-säure [German] [ACD/IUPAC Name]
2-[2-[2-[[2-[2-(2-Aminoethoxy)ethoxy]acetyl]amino]ethoxy]ethoxy]acetic acid
20802384 [Beilstein]
3,6,12,15-Tetraoxa-9-azaheptadecan-1-oic acid, 17-amino-10-oxo- [ACD/Index Name]
Acide 17-amino-10-oxo-3,6,12,15-tétraoxa-9-azaheptadécan-1-oïque [French] [ACD/IUPAC Name]
Z2O2O1VM2O2O1VQ [WLN]
[2-(2-{2-[2-(2-AMINOETHOXY)ETHOXY]ACETAMIDO}ETHOXY)ETHOXY]ACETIC ACID
2-[2-(2-{2-[2-(2-AMINOETHOXY)ETHOXY]ACETAMIDO}ETHOXY)ETHOXY]ACETIC ACID
Aeea-aeea
H-AEEA-AEEA
H-AEEA-AEEA-OH
MFCD13184942 [MDL number]

SMILES

C(COCCOCC(=O)NCCOCCOCC(=O)O)N

StdInChI

InChI=1S/C12H24N2O7/c13-1-3-18-5-7-20-9-11(15)14-2-4-19-6-8-21-10-12(16)17/h1-10,13H2,(H,14,15)(H,16,17)

StdInChIKey

YQZVQKYXWPIKIX-UHFFFAOYSA-N

Molecular Formula

C12H24N2O7

Molecular Weight

308.328

MDL Number

MFCD13184942

Properties

Appearance

Powder

Structure

Structure of 17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecanoic Acid CAS 1143516-05-5
Structure of 17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecanoic Acid CAS 1143516-05-5

Safety Data

Symbol

exclamation-mark-jpgGHS07

Signal Word

Warning

Hazard statements

H302-H315-H319-H335

Precautionary Statements

P261-P280-P301+P312-P302+P352-P305+P351+P338

WGK Germany

3

MSDS Download

Specifications and Other Information of Our

Identification Methods

HPLC

Purity

98% min

Shelf Life

1 year

Storage

Storage at 2~8°

Known Application

As an intermediate in the synthesis of semaglutide, 17-amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecanoic acid likely plays a crucial role in the production of this medication. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes.

1.Using this intermediate in the synthesis of semaglutide can allow for greater control over the purity and quality of the final product. Intermediate compounds are often purified at each step of the synthesis, helping to remove impurities.

2.And developing an efficient synthesis route with this intermediate could contribute to the cost-effectiveness of producing semaglutide.

General View of Documents

This product is developed by our R&D company Caming Pharmaceutical Limited (http://www.caming.com/).

This product is sold exclusively through our sales company Watson International Limited, and please click the link below for details (https://www.watson-int.com/).